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Abstract 
A quantitative structure-activity relationship (QSAR) study has been made on some series of anti-hepatitis B virus (HBV) agents, namely, a 
series of novel bis(L-amino acid) ester prodrugs of 9-[2-(phosphonomethoxy)ethyl]adenine, a similar series of compounds comprising of 2-
amino-6-arylthio-9-[2-(phosphonoethoxy)ethyl]purine bis(2,2,2- trifluoroethyl) esters, and a series of 1-isopropylsulfonyl-2-amine 
benzimidazoles. In each case significant correlations are found between the anti-HBV potencies and some physicochemical and steric 
properties of the compounds, indicating that for the first two series the activity is controlled by the hydrophobic and the bulk properties of 
the molecules and, for the third series, the steric and hydrogen bonding properties of compounds are  crucial for their anti-HBV potency.  
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Background: 
Hepatitis B Virus (HBV) infection has now become one of the most 
dangerous diseases of the world.  It causes both acute and chronic 
hepatitis [1]. Chronic HBV infection can lead to cirrhosis, liver 
failure and hepatocellular carcinoma [2, 3].  Presently, there are 
only few agents, namely α-interferon (IFN-α), i.e., lamivudine (3-
Tc)  (1), adefovir dipivoxil (2), and entacavir (3), that have been 
approved for clinical treatment. However,   all these drugs suffer 
from serious side effects. Interferon-α, an immunomodulator and the 
first therapeutic agent developed to treat HBV infection, has very 
low cure rate (effective only to 30-40% patients) and produces 
many side effects [4]. The three nucleoside analogs, lamivudine, 
adefovir dipivoxil, and entacavir, are supposed to elicit their effects 
mainly through the inhibition of HBV polymerase leading to 
decrease in viral replication [5]
.  All these three drugs suffer from 
high relapse rates after the cessation of the treatment [6]
.  
Lamivudine has the potential of inducing drug resistant HBV after 
few months of therapy, and causes an associated risk of increase of 
viremia during the therapy in HBV patients.  Although a 
combination therapy of lamivudine and adefovir dipivoxil may be 
more fruitful [7] since both have excellent activity and oral 
bioavailability and the combination has good tolerability and 
reduced potential to produce drug resistant HBV, this therapy is still 
limited  [8]
.  Therefore, the medicinal chemists are paying high 
attention to design and develop novel classes of anti- HBV agents 
that may have optimal pharmacological profiles with little side 
effects. In this respect, the quantitative structure- activity 
relationship (QSAR) studies have been of great importance. They 
not only provide guidelines for the drug design but also throw the 
light on the mechanisms of drug-receptor interactions, which further 
aid to the rationalization of drug development.  We, therefore, 
present here a QSAR study on some important series of HBV 
inhibitors. 
 
Methodology: 
We have taken three different series of HBV inhibitors that were 
synthesized and studied for their anti-HBV activity.  Recently, a 
series of novel bis (L-amino acid) ester prodrugs of 9-[2-
(phosphonomethoxy)ethyl]adenine (4) was synthesized and reported 
for their anti-HBV and toxic activities by Fu et al. [9]
  and a similar 
series of compounds comprising of 2-amino-6-arylthio-9-[2- 
(phosphonoethoxy)ethyl] purine bis(2, 2, 2- trifluoroethyl) esters (5) 
was earlier studied by Sekiya et al.[10]
 .  However, an entirely new 
class of anti-HBV agents comprising of 1-isopropylsulfonyl-2-
amine benzimidazoles (6, 7) was reported by Li et al. [11]. The first 
two series of compounds are listed I Tables 1 and 2,  (see 
supplementary material) respectively. A combine of these two is 
listed in Table 3, and Table 4 (see supplementary material) lists 
the derivatives of 6 and 7. These tables also list the anti-HBV and 
toxic activities of the compounds and their physicochemical 
parameters that were found to govern their potency.  Among the 
physicochemical parameters listed in different tables, ClogP and 
CMR refer to calculated hydrophobicity and molar refractivity of 
the compounds, respectively, Es is Taft’s steric constant, and B1 is a 
STERIMOL parameter, a steric parameter referring to the minimum 
width of the substituent [12]
 .ClogP and CMR have been calculated 
from ChemDraw version 8.0, and values of B1 have been taken 
from the literature [13].  In the activity term log (1/EC50), EC50 
refers to molar concentration of the compound achieving 50% 
inhibition of cytoplasmic HBV DNA synthesis, and in toxicity term 
log (1/CC50), CC50 refers to the molar concentration of the 
compound leading to 50% extinction of HepG2.2.15 cells. 
 
Results and Discussion: 
A multiple regression analysis performed on anti-HBV and toxic 
data of Fu et al. on bis(L-amino acid) ester prodrugs and 9-[2-
phosphonomethoxy)ethyl]adenine (Table 1)  (see supplementary 
material) had revealed the correlations in Equations 1 and 2 (see 
supplementary material). In these Equations, n is the number of 
data points, r is the correlation coefficient, rcv
2 is the square of cross-
validated correlation coefficient obtained by leave-one-out (LOO) 
jackknife procedure, F is the F-ratio between the variances of 
calculated and observed activities (data within parentheses refer to 
standard F-values at 99% level), and the figures with ± sign 
following the coefficients of the variables are 95% confidence 
intervals.  Now Eq. 1 exhibits that the anti-HBV activity of this 
class of compounds is solely controlled by the lipophilicity of the 
molecules and has a simple linear dependence on ClogP.  The rcv
2  
greater than 0.6 shows a good predictive ability of the Equation.  
However, the toxic data of this series of compounds was not found 
to be linearly dependent on ClogP, rather is shown to have a 
parabolic correlation (inverted parabola) with optimum ClogP value 
equal to zero. This means that the compound may have the lowest 
toxic effect when ClogP is zero. Further, Eq. 2 shows that the toxic 
effect of the compounds will be lower; the higher is its molar 
refractivity. The molar refractivity refers to the size of the molecule, 
so larger is the molecule, the lower would be its toxic effect. Thus 
we can have a good selective index of the compounds by increasing 
their bulkiness, maintaining their ClogP values.   However, for the 
compounds of Table 2 (see supplementary material), which are 
structurally very similar to those of Table 1 (see supplementary 
material), the anti-HBV activity was found to have negative 
dependence on ClogP as well as on CMR (Eq. 3). If we compare the 
ClogP values of these compounds with ClogP values of compounds 
of Table 1 (see supplementary material), we find that these values 
are much higher than those in Table 1 (see supplementary 
material), and thus it can be concluded that higher values of ClogP 
may be detrimental to the activity. So there should be a limit to the 
value of ClogP. To find this thing, we combined both the series of 
compounds (Table 3) (see supplementary material) and obtained Bioinformation   open access 
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the correlation as shown by Eq. 4. This Equation gives an optimum 
value of ClogP equal to 1.80. Thus, Equations 3 and 4 are formed 
(see supplementary material). The activity will have a positive 
dependence on ClogP only until its value does not reach 1.80. 
Beyond that, the activity will decrease as ClogP increases. In Table 
2 (see supplementary material), none of the compounds has its 
ClogP value less than 1.80, hence we got a negative correlation with 
ClogP. On the other hand, in Table 1, none of the compounds has 
its ClogP value greater than 1.80, hence in this case a positive 
correlation with ClogP was found. Since the lipophilicity of the 
compounds also depends on the size of the molecule, for highly 
hydrophobic molecules the molar refractivity has also cropped up to 
play a negative role in Equation 4 (see supplementary material) 
derived for the combine. For Table 2 (see supplementary 
material), we were unable to correlate the toxic effects of the 
compounds with any parameters. The reason being that there was 
little span in the toxic data. However, when we combined them with 
that of compounds of Table 1 (see supplementary material), a 
similar Equation, as found for Table 1 (see supplementary 
material) itself, was obtained (Equation 5 in supplementary 
material).                                                                                                                                                  
This Equation, too, suggests that toxicity can be minimum when 
ClogP = 0, i.e., when there is a balance between the solubilities of 
the compound in lipid and aqueous phases, and it can be further 
controlled by controlling the size of the molecule. A control in size 
will also be beneficial to anti-HBV activity, but a limit of ClogP 
equal to zero will be slightly unsatisfactory for it. For better anti-
HBV potency, ClogP should approach to 1.80 as Eq. 4 suggests.   
For the compounds of Table 4 (see supplementary material), the 
anti-HBV activity was found to be correlated with Taft’s steric 
parameter Es,  STERIMOL parameter B1 that describes the 
minimum width of the substituent, and an indicator parameters I1 
(Equation 6) (see supplementary material). The indicator 
parameter I1 has been used for regioisomerism of the compounds. 
For all the derivatives of 6, I2 = 1 and for all the derivatives of 7, I2 = 
0. The positive coefficient of this parameter indicates that in general 
6-substituted isomers (6) would be more active than 5- Substituted 
ones (7).  The reason of this may be that in the former the phenyl 
ring may be better oriented towards the active site of the receptor 
for interaction than in the latter. The occurrence of the Es parameter 
in the Equation suggests that there would be some steric effect of 
the R-substituents and since Es usually have negative values, the 
positive coefficient of it in the equation indicates that the bigger 
substituents may not be conducive to the activity. However, a 
positive coefficient of B1 suggests that the width of the substituent 
may be beneficial. The toxic effects for some of these compounds 
were also reported, but we could not find any good correlation for 
them.  All the equations mentioned here represent statistically 
highly significant correlations, but in deriving each one, certain 
compounds that behaved as outliers were removed. These 
compounds are indicated in respective tables.  However, no 
convincing reasons could be assigned for the aberrant behavior of 
these compounds in most of the cases. Outliers, in general, are a 
problem in QSAR, but sometimes they provide important clue to the 
drug design. An excellent and the only example of this here is Eq. 6, 
which has been derived for Table 4 (see supplementary material). 
The outliers of this equation are compounds 6a and 6i, from which 
we can derive some important information. For compound 6a, the 
observed activity is much lower than that predicted by Equation 6. 
This compound has no substituent at the phenyl ring, so its low 
observed activity can be attributed to the absence of any substituent 
at the phenyl ring in this compound. And consequently it can be 
suggested that the substitution at the phenyl ring is essential for the 
good activity of the compound. Compound 6i, which has an NO2 
group at the 3-position of the phenyl ring, also has a lower observed 
activity than the predicted one. The reason of this may be that nitro 
group may be involved in the formation of intramolecular hydrogen 
bond with the NH moiety in the bridge, a moiety that otherwise may 
presumably form a hydrogen bond with the receptor. Thus, this 
outlier indicates that the NH moiety may definitely be involved in 
the hydrogen bonding with the receptor, strengthening the drug-
receptor interaction. Not only this, one can also assume that the 
whole carboxamide (-CONH-) or sulphonamide (-SO2NH-) bridge 
group may be involved in the hydrogen bonding with the receptor, 
since  CO and SO2 are also able to do so acting  as H-bond 
acceptors, while NH may act as H-bond donor.  
 
Conclusion: 
This QSAR analysis has shown that for certain series of anti-HBV 
agents, such as  the series of novel bis(L-amino acid) ester prodrugs 
of 9-[2-(phosphonomethoxy)ethyl]adenine (4) and the similar series 
of compounds comprising of 2-amino-6-arylthio-9-[2-
(phosphonoethoxy)ethyl]purine  bis(2, 2, 2- trifluoroethyl) esters 
(5), the hydrophobic property and the bulk of the molecules are very 
crucial. However, for the agents, such as 1-isopropylsulfonyl-2-
amine benzimidazoles, this study has pointed out that the 
substitution at the phenyl ring and the steric properties of those 
substituents are highly important for their anti-HBV activity and 
that the hydrogen bonding ability of carboxamide or sulphonamide 
group, bridging the phenyl and benzimidazole rings, may be of 
further advantage because of their ability to form the hydrogen 
bonds with the receptor. Thus, the receptor of HBV inhibitors (HBV 
polymerase) can be assumed to possess an active site that may be 
capable of forming the hydrogen-bonds with the compounds. 
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Supplementary material: 
 
log(1/EC50) = 0.489(±0.143)ClogP + 6.069(±0.177)  
n = 11, r = 0.933, rcv
2 = 0.79, s = 0.26, F1, 9 = 60.19(10.56)                                               (1) 
 
log(1/CC50 ) = − 0.104(±0.101)CMR + 0.282(±0.136)(ClogP)
 2 + 3.391(±1.564) 
n = 10, r = 0.935,  rcv
2 = 0.71, s = 0.23, F2, 7 = 24.19(9.55), (ClogP) opt = 0.0                     (2)           
 
log(1/EC50)  = − 0.369(±0.347)ClogP − 0.571(±0.344)CMR + 15.159(±3.576) 
n = 14, r = 0.905, rcv
2 = 0.72, s = 0.24, F 2, 11 =24.92(7.20)                                                (3) 
 
log(1/EC50) = 0.595(±0.126)ClogP – 0.165(±0.045) (ClogP)
2 – 0.177(±0.091) CMR + 9.010(±1.347) 
n = 25, r = 0.910, rcv
2 = 0.65, s = 0.30, F 3, 21 = 33.69(4.87), (ClogP)opt = 1.80                 (4) 
 
log(1/CC50) = − 0.158(±0.087)CMR + 0.071(±0.021)(ClogP)
2  + 4.664(±1.279) 
n = 23, r = 0.923, , rcv
2 = 0.68, s = 0.30, F 2, 20 = 57.52(5.85), (ClogP) opt = 0.0                   (5)         
 
log(1/EC50) = 0.761(±0.403)Es + 0.528(±0.423)B1 + 0.486(±0.357)I1+ 5.057(±0.544) 
n = 10, r = 0.925, s = 0.200, F3,6 = 11.77(9.78), rcv
2 = 0.48                                                  (6)        
     
 
 
Table 1: Bis (L-amino acid) ester prodrugs of 9-[2-(phosphonomethoxy) ethyl] adenine and their anti-HBV and toxic activities and 
physicochemical parameters                                                          
     log(1/EC50)
a log(1/  CC50)
a   
Compd 
 
R 
 
X 
 
n 
 
ClogP 
 
CMR 
Obsd 
 
Cald, 
Eq. 1 
Pred, 
LOO 
Obsd 
 
Cald, 
Eq. 2 
Pred, 
LOO 
4a  Me O  2  −1.75  11.94  4.90 5.21 5.34 2.73 3.01 3.15 
4b  Isopropyl O 2     0.10  13.79 5.88  6.12  6.14  2.59
c 1.96    − 
4c  2-Me-Pr  O  2    1.16  14.72  7.02  6.64  6.56  2.18  2.32  2.25 
4d  Bz  O  2    1.08  16.96  6.51  6.60  6.61  2.59
c 1.96    − 
4e  H S  2  −2.16  12.14  4.99 5.01 5.02 3.59 3.44 3.24 
4f  Me S  2  −1.54  13.24  5.81 5.31 5.15 2.62 2.63 2.69 
4g  Isopropyl  S  2    0.31  15.10  6.12  6.22  6.23  1.54  1.82  1.92 
4h  2-Me-Pr   S  2    1.37  16.02  6.67  6.74  6.75  2.47  2.32  2.20 
4i  Bz  S  2    1.29  18.26  6.68  6.70  6.70  1.96  1.93  1.98 
4j  Isopropyl O 1 −0.46  12.86 6.52
b 5.84    −  2.47 2.10 1.90 
4k  2-Me-Pr   O  1    0.59  13.79  6.47  6.36  6.34  2.07  2.10  2.06 
4l  Bz  O  1    0.51  16.03  6.18  6.32  6.33  1.81  1.75  1.79 
aTaken from ref [9]. 
bNot included in the derivation of Eq. 1. 
c Not included in the derivation of Eq. 2. 
 
Table 2: 2-Amino-6-arythio-9-[2-(phosphonomethoxy) ethyl]purine bis (2,2,2-trifluoroethyl) esters and their anti-HBV and toxic activities 
and physicochemical parameters.                                                                                         
          log(1/ EC50) log(1/CC50)   
Compd 
 
R 
 
ClogP 
 
CMR 
Obsd
a Cald   
Eq. 3 
Pred LOO    Obsd
a 
5a  SPh  2.95  11.45  7.30  7.54  7.62     NA
b 
5b  SPh(4-Me)  3.45  11.91  7.22  7.09  7.07     3.96 
5c  SPh(3-Me)  3.45  11.91  7.04  7.09  7.10     3.82 
5d  SPh(2-Me)  3.45  11.91  7.10  7.09  7.09     3.47 Bioinformation   open access 
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5e  SPh(4-Et)  3.98  12.38  6.40  6.63  6.67     3.77 
5f  SPh(4-iPr)  4.38  12.84  6.01  6.22  6.29     3.77 
5g  SPh(4-NO2) 2.70  12.06  6.28
c 7.28   −     3.42 
5h  SPh(4-Cl)  3.67  11.94  6.92  6.99  7.00     4.21 
5i  SPh(4-OMe)  2.87  12.06  7.52  7.22  7.15     NA 
5j  SPh(3-OMe)  2.87  12.06  7.40  7.22  7.19     NA 
5k  SPh(2-OMe)  2.47  12.06  7.10  7.37  7.56     NA 
5l  SPh(4-OEt) 3.40  12.53  6.19
c 6.75   −     NA 
5m  SPh(4-O-nPr)  3.93  12.99  6.06  6.30  6.35     3.60 
5n  SPh(4-O-iPr)  3.71  12.99  6.54  6.38  6.34     3.45 
5o  SPh(4-O-nBu) 4.46  13.46 NA  NA    −     3.58 
5p  SPh(4-O-iBu)  4.11  13.46  6.07  5.96  5.89     4.00 
5q  SPh(4-O-CF3)  3.98  12.11  7.22  6.78  6.66     3.09 
 
5r  S-(2-naphthyl) 4.13  13.14 7.04
c 6.13   −     3.70 
aTaken from ref [10].
bNA: Not available. 
cNot included in the derivation of Eq. 3. 
 
Table 3: A combine of Tables 1 and 2 
                  log(1/EC50)                  log(1/CC50)   
Compd 
 
ClogP 
 
CMR 
Obsd Cald 
Eq. 4 
Pred 
LOO 
Obsd Cald 
Eq. 5 
Pred 
LOO 
4a  −1.75  11.94  4.90 5.35 5.53 2.73 2.99 3.05 
4b    0.10  13.79  5.88
a 6.63  −  2.59 2.49 2.48 
4c    1.16  14.72  7.02  6.87  6.66  2.18  2.44  2.46 
4d    1.08  16.96  6.51  6.45  6.45  2.59  2.07  1.92 
4e  −2.16  12.14  4.99 4.81 4.66 3.59 3.07 3.02 
4f  −1.54  13.24  5.81 5.36 5.23 2.62 2.74 2.76 
4g    0.31  15.10  6.12  6.50  6.54  1.54
c 2.29  − 
4h    1.37  16.02  6.67  6.68  6.68  2.47  2.27  2.24 
4i    1.29  18.26  6.68  6.27  6.03  1.96  1.90  1.86 
4j  −0.46  12.86  6.52 6.42 6.40 2.47 2.65 2.69 
4k    0.59  13.79  6.47  6.86  6.91  2.07  2.51  2.57 
4l    0.51  16.03  6.18  6.43  6.46  1.81  2.16  2.21 
5a    2.95  11.45  7.30  7.30  7.31  NA  NA  NA 
5b    3.45  11.91  7.22  6.99  6.98  3.96  3.63  2.85 
5c    3.45  11.91  7.04  6.99  6.99  3.82  3.63  3.61 
5d    3.45  11.91  7.10  6.99  6.98  3.47  3.63  3.65 
5e    3.98  12.38  6.40  6.58  6.59  3.77  3.83  3.83 
5f    4.38  12.84  6.01  6.18  6.25  3.77  3.99  4.05 
5g    2.70  12.06  6.28
 a 7.29  −  3.42 3.28 3.26 
5h    3.67  11.94  6.92  6.86  6.85  4.21  3.74  3.68 
5i    2.87  12.06  7.52  7.22  7.19  NA  NA  NA 
5j    2.87  12.06  7.40  7.22  7.20  NA  NA  NA 
5k    2.47  12.06  7.10  7.34  7.38  NA  NA  NA 
5l    3.40  12.53  6.19
 a 6.90  −  NA NA NA 
5m    3.93  12.99  6.06  6.51  6.58  3.60  3.71  3.72 
5n    3.71  12.99  6.54  6.65  6.29  3.45  3.59  3.60 
5o    4.46  13.46  NA
 b NA  NA  3.58 3.95 4.04 
5p    4.11  13.46  6.07  6.29  6.36  4.00  3.74  3.71 
5q    3.98  12.11  7.22  6.63  6.56  3.09  3.88
c  − 
5r    4.13  13.14  7.04
 a 6.34  −  3.70 3.80 3.82 
  aNot included in the derivation of Eq. 4. 
bNA: Not available. 
c Not included in the derivation of Eq. 5. 
 
 
Table 4: 1-Isopropylsulfonyl-2-amine benzimidazoles and their anti-HBV and toxic activities and physicochemical parameters                                                     
          log (1/EC50)  Compd  
 X 
  
   R 
  
    Es 
 
  B1 
 
  I1  Obsd
a Calcd 
Eq. 6  
Pred 
LOO 
6a
b  CO  H    0.00  1.00  1.00  4.47   6.07    − 
6b  CO 2-F  −0.46  1.35 1.00 6.03    5.91  5.88 
6c  CO 4-F  −0.46  1.35 1.00 5.92    5.91  5.90 
6d  CO 2,6-DiF  −0.92  2.70 1.00 6.15    6.27  7.53 
6e  CO 2-Cl  −0.97  1.80 1.00 6.09    5.75  5.68 
6f  CO 4-CH3  −1.24  1.52 1.00 5.38    5.40  5.41 
6g  SO2  H    0.00  1.00  1.00  5.82   6.07  6.28 
6h  SO2  4-CH3  −1.24  1.52 1.00 5.32    5.40  5.44 
6i
b  SO2  3-NO2  −1.01  1.70 1.00 4.98    5.67    − 
7a  CO  H    0.00  1.00  0.00  5.70   5.85  5.47 
7b  CO 4-F  −0.46  1.35 0.00 5.43    5.42  5.41 
aTaken from ref [11].
 bNot included in the derivation of Eq. 6. 